When will X4 Pharmaceuticals report its third-quarter financial results?

X4 Pharmaceuticals will report its third-quarter financial results and the results from a Phase 2 clinical trial on November 13, 2024.

What time is the conference call scheduled for?

The conference call will take place at 8:00 a.m. ET on November 13, 2024.

How can investors participate in the conference call?

Investors can access the conference call by dialing 1-800-267-6316 in the U.S. or 1-203-518-9783 internationally with the conference ID: X4PHARMA.

What is mavorixafor and what has it been approved for?

X4 Pharmaceuticals is developing mavorixafor for rare diseases of the immune system, and it has received U.S. approval for its first indication under the name XOLREMDI.

Will there be a replay of the conference call available for investors?

The presentation will be available on X4 Pharmaceuticals' investor relations website for replay after the call.

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

10/24/24 8:00:00 AM ET

$XFOR

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $XFOR alert in real time by email

BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the third quarter ended September 30, 2024 and present results from its concluded Phase 2 clinical trial evaluating mavorixafor in people with chronic neutropenia on Wednesday, November 13, 2024.

The company will host a conference call and webcast on the same day at 8:00 a.m. ET. The conference call can be accessed by dialing 1-800-267-6316 from the United States or 1-203-518-9783 internationally, followed by the conference ID: X4PHARMA. The live webcast and accompanying slide presentation will be accessible through the investor relations section of X4 Pharmaceuticals' website at www.x4pharma.com. Following the conclusion of the call and webcast, a replay will be available on the company's website.

About X4 Pharmaceuticals

X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI^® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.

Company Contact:

José Juves

Head of Corporate & Patient Affairs

[email protected]

Investor Contact:

Daniel Ferry

Managing Director, LifeSci Advisors

[email protected]

(617) 430-7576

Get the next $XFOR alert in real time by email

Date	Price Target	Rating	Analyst
12/12/2023	$3.00 → $1.00	Buy → Neutral	B. Riley Securities
8/30/2023	$3.00	Buy	B. Riley Securities
12/22/2022	$3.00	Overweight	Cantor Fitzgerald
12/12/2022	$3.00	Overweight	Piper Sandler
12/14/2021	$21.00 → $11.00	Buy	HC Wainwright & Co.

Date

Price Target

Rating

Analyst

12/12/2023

$3.00 → $1.00

Buy → Neutral

B. Riley Securities

8/30/2023

$3.00

Buy

B. Riley Securities

12/22/2022

$3.00

Overweight

Cantor Fitzgerald

12/12/2022

$3.00

Overweight

Piper Sandler

12/14/2021

$21.00 → $11.00

Buy

HC Wainwright & Co.

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

Chat with this insight

Q&A

When will X4 Pharmaceuticals report its third-quarter financial results?

What time is the conference call scheduled for?

How can investors participate in the conference call?

What is mavorixafor and what has it been approved for?

Will there be a replay of the conference call available for investors?

Recent Analyst Ratings for $XFOR

$XFOR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

X4 Pharmaceuticals downgraded by B. Riley Securities with a new price target

B. Riley Securities resumed coverage on X4 Pharmaceuticals with a new price target

Cantor Fitzgerald initiated coverage on X4 Pharmaceuticals with a new price target

$XFOR SEC Filings

SEC Form 10-Q filed by X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

X4 Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$XFOR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President and CEO Ragan Paula sold $12,583 worth of shares (31,897 units at $0.39), decreasing direct ownership by 3% to 993,919 units (SEC Form 4)

President and CEO Ragan Paula sold $17,926 worth of shares (31,897 units at $0.56), decreasing direct ownership by 3% to 1,025,816 units (SEC Form 4)

Chief Financial Officer Mostafa Adam S. was granted 230,645 shares and sold $126,901 worth of shares (230,645 units at $0.55) (SEC Form 4)

$XFOR Financials

Live finance-specific insights

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)